Restart Life Sciences Corp.
HEAL
Rangering i aksjer
#35840
Operating internationally through its various subsidiaries, Restart Life... Operating internationally through its various subsidiaries, Restart Life Sciences Corp. functions as a biotechnology firm. Its core endeavors include the creation of natural therapeutic remedies tailored for individuals with autism spectrum disorder, the development of health-promoting foods designed for comprehensive mind and body wellness, and the execution of a psilocybin clinical trial aimed at fragile X syndrome. Founded in 2004 and based in Vancouver, Canada, the company adopted its current name in November 2024, having previously been known as Nova Mentis Life Science Corp.
Aksjekurs
$0.05137558
Sist synkronisert: 2026-10-16
Markedsverdi
$3.21M
Endring (1 dag)
0.00%
Endring (1 år)
78.84%
Land
CA
Handel Restart Life Sciences Corp. (HEAL)
Kategori
Healthcare
EPS for Restart Life Sciences Corp. (HEAL)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Restart Life Sciences Corp. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Restart Life Sciences Corp. fra 2026 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| - | - |
CH
|
|
| $27.74 | - |
NL
|
